Skip to main content
Premium Trial:

Request an Annual Quote

Denis O’Shaughnessy

Premium
Acuity Pharmaceuticals has appointed Denis O’Shaughnessy as its senior vice president of clinical development.
 
O’Shaughnessy was formerly senior vice president of clinical development and co-founder of Eyetech Pharmaceuticals, where he oversaw development of the wet age-related macular degeneration drug Macugen. Before this, he was director of clinical operations and department head at Hoffman-La Roche. He has also held positions at Cyanamid, Sandoz, Xoma, and Celltech.
 
“As we prepare to move into later stage trials with our lead compound bevasiranib, this experience should be of tremendous value in ensuring that our clinical program is optimally designed and executed,” Acuity President and CEO Dale Pfost said in a statement.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.